Cantargia AB (publ) (CANTA.ST)
SEK 1.83
(1.05%)
SEK 1.83
(1.05%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 223.71 Million SEK | -52.88% |
| 2022 | 474.79 Million SEK | -20.9% |
| 2021 | 600.24 Million SEK | -35.14% |
| 2020 | 925.51 Million SEK | 457.35% |
| 2019 | 166.05 Million SEK | -3.14% |
| 2018 | 171.44 Million SEK | -37.53% |
| 2017 | 274.45 Million SEK | 477.66% |
| 2016 | 47.51 Million SEK | 51.39% |
| 2015 | 31.38 Million SEK | 55.91% |
| 2014 | 20.12 Million SEK | 404.52% |
| 2013 | 3.98 Million SEK | 5.7% |
| 2012 | 3.77 Million SEK | 57.03% |
| 2011 | 2.4 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 171.37 Million SEK | -23.4% |
| 2024 Q2 | 121.95 Million SEK | -28.84% |
| 2023 FY | 223.71 Million SEK | -52.88% |
| 2023 Q2 | 341.48 Million SEK | -16.42% |
| 2023 Q3 | 238.91 Million SEK | -30.04% |
| 2023 Q4 | 223.71 Million SEK | -6.36% |
| 2023 Q1 | 408.56 Million SEK | -13.95% |
| 2022 Q4 | 474.79 Million SEK | -12.68% |
| 2022 Q1 | 509.48 Million SEK | -15.12% |
| 2022 Q2 | 394.67 Million SEK | -22.54% |
| 2022 FY | 474.79 Million SEK | -20.9% |
| 2022 Q3 | 543.72 Million SEK | 37.76% |
| 2021 Q2 | 806.97 Million SEK | -7.9% |
| 2021 Q3 | 697.94 Million SEK | -13.51% |
| 2021 Q4 | 600.24 Million SEK | -14.0% |
| 2021 Q1 | 876.21 Million SEK | -5.33% |
| 2021 FY | 600.24 Million SEK | -35.14% |
| 2020 FY | 925.51 Million SEK | 457.35% |
| 2020 Q3 | 444.8 Million SEK | -8.19% |
| 2020 Q2 | 484.5 Million SEK | -5.77% |
| 2020 Q4 | 925.51 Million SEK | 108.07% |
| 2020 Q1 | 514.17 Million SEK | 209.64% |
| 2019 Q2 | 224.49 Million SEK | -12.48% |
| 2019 Q1 | 256.5 Million SEK | 49.62% |
| 2019 FY | 166.05 Million SEK | -3.14% |
| 2019 Q4 | 166.05 Million SEK | -22.34% |
| 2019 Q3 | 213.82 Million SEK | -4.75% |
| 2018 Q4 | 171.44 Million SEK | -12.47% |
| 2018 Q3 | 195.87 Million SEK | -10.58% |
| 2018 FY | 171.44 Million SEK | -37.53% |
| 2018 Q1 | 251.47 Million SEK | -8.37% |
| 2018 Q2 | 219.04 Million SEK | -12.9% |
| 2017 Q4 | 274.45 Million SEK | 307.07% |
| 2017 FY | 274.45 Million SEK | 477.66% |
| 2017 Q1 | 97.39 Million SEK | 104.99% |
| 2017 Q2 | 80.5 Million SEK | -17.33% |
| 2017 Q3 | 67.42 Million SEK | -16.26% |
| 2016 Q3 | 39.32 Million SEK | -18.87% |
| 2016 FY | 47.51 Million SEK | 51.39% |
| 2016 Q4 | 47.51 Million SEK | 20.8% |
| 2016 Q2 | 48.47 Million SEK | 88.96% |
| 2016 Q1 | 25.65 Million SEK | -18.26% |
| 2015 Q2 | 39.47 Million SEK | -10.17% |
| 2015 FY | 31.38 Million SEK | 55.91% |
| 2015 Q1 | 43.94 Million SEK | 118.32% |
| 2015 Q4 | 31.38 Million SEK | -7.94% |
| 2015 Q3 | 34.09 Million SEK | -13.65% |
| 2014 Q4 | 20.12 Million SEK | -4.46% |
| 2014 Q1 | - SEK | -100.0% |
| 2014 FY | 20.12 Million SEK | 404.52% |
| 2014 Q3 | 21.06 Million SEK | 0.0% |
| 2013 Q4 | 3.98 Million SEK | 0.0% |
| 2013 FY | 3.98 Million SEK | 5.7% |
| 2012 FY | 3.77 Million SEK | 57.03% |
| 2011 FY | 2.4 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 118.45 Million SEK | -88.866% |
| Ziccum AB (publ) | 14.97 Million SEK | -1394.203% |
| Modus Therapeutics Holding AB (publ) | 20.04 Million SEK | -1016.272% |
| BioArctic AB (publ) | 1.18 Billion SEK | 81.139% |
| Sprint Bioscience AB (publ) | 62.37 Million SEK | -258.645% |
| Mendus AB (publ) | 755.95 Million SEK | 70.407% |
| Genovis AB (publ.) | 288.85 Million SEK | 22.553% |
| Intervacc AB (publ) | 259.61 Million SEK | 13.828% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 41.95 Million SEK | -433.168% |
| Active Biotech AB (publ) | 44 Million SEK | -408.436% |
| Magle Chemoswed Holding AB (publ) | 278.74 Million SEK | 19.743% |
| Bio-Works Technologies AB (publ) | 62.15 Million SEK | -259.943% |
| Aptahem AB (publ) | 63.02 Million SEK | -254.958% |
| Vicore Pharma Holding AB (publ) | 496.24 Million SEK | 54.919% |
| Kancera AB (publ) | 65.64 Million SEK | -240.801% |
| Infant Bacterial Therapeutics AB (publ) | 351.33 Million SEK | 36.325% |
| Fluicell AB (publ) | 9.34 Million SEK | -2295.203% |
| Saniona AB (publ) | 64.14 Million SEK | -248.771% |
| Lipigon Pharmaceuticals AB (publ) | 33.6 Million SEK | -565.77% |
| Biovica International AB (publ) | 131.4 Million SEK | -70.242% |
| Spago Nanomedical AB (publ) | 52.98 Million SEK | -322.218% |
| AcouSort AB (publ) | 34.51 Million SEK | -548.196% |
| Xintela AB (publ) | 18.39 Million SEK | -1116.157% |
| Abliva AB (publ) | 87.49 Million SEK | -155.674% |
| Egetis Therapeutics AB (publ) | 760.2 Million SEK | 70.572% |
| Karolinska Development AB (publ) | 1.25 Billion SEK | 82.222% |
| OncoZenge AB (publ) | 20.34 Million SEK | -999.862% |
| Amniotics AB (publ) | 26.08 Million SEK | -757.594% |
| 2cureX AB (publ) | 16.62 Million SEK | -1245.636% |
| CombiGene AB (publ) | 120.61 Million SEK | -85.481% |
| Asarina Pharma AB (publ) | 6.07 Million SEK | -3581.29% |
| Calliditas Therapeutics AB (publ) | 1.9 Billion SEK | 88.229% |
| Camurus AB (publ) | 1.9 Billion SEK | 88.274% |
| Corline Biomedical AB | 100.1 Million SEK | -123.477% |
| IRLAB Therapeutics AB (publ) | 177.12 Million SEK | -26.305% |
| Isofol Medical AB (publ) | 140.59 Million SEK | -59.116% |
| I-Tech AB | 152.44 Million SEK | -46.751% |
| Hansa Biopharma AB (publ) | 1.01 Billion SEK | 78.025% |
| Cyxone AB (publ) | 43.65 Million SEK | -412.454% |
| ExpreS2ion Biotech Holding AB (publ) | 78.69 Million SEK | -184.288% |
| Biosergen AB | 7.2 Million SEK | -3006.68% |
| NextCell Pharma AB | 81.28 Million SEK | -175.209% |
| Xspray Pharma AB (publ) | 765.26 Million SEK | 70.767% |
| Elicera Therapeutics AB (publ) | 30.17 Million SEK | -641.43% |
| Nanologica AB (publ) | 77.42 Million SEK | -188.925% |
| SynAct Pharma AB | 228.01 Million SEK | 1.889% |
| Annexin Pharmaceuticals AB (publ) | 26.76 Million SEK | -735.9% |
| Stayble Therapeutics AB (publ) | 21.7 Million SEK | -930.794% |
| LIDDS AB (publ) | 17.65 Million SEK | -1167.131% |
| Lipum AB (publ) | 12.11 Million SEK | -1747.333% |
| BioInvent International AB (publ) | 1.4 Billion SEK | 84.023% |
| Alzinova AB (publ) | 123.18 Million SEK | -81.601% |
| Oncopeptides AB (publ) | 238.37 Million SEK | 6.152% |
| Pila Pharma AB (publ) | 8.45 Million SEK | -2545.914% |
| Guard Therapeutics International AB (publ) | 85.22 Million SEK | -162.49% |
| Scandinavian ChemoTech AB (publ) | 14.86 Million SEK | -1404.553% |
| Simris Alg AB (publ) | 174.55 Million SEK | -28.164% |
| Diamyd Medical AB (publ) | 217.03 Million SEK | -3.075% |
| Xbrane Biopharma AB (publ) | 653.5 Million SEK | 65.768% |
| Ascelia Pharma AB (publ) | 87.07 Million SEK | -156.928% |
| Diagonal Bio AB (publ) | 28.5 Million SEK | -684.734% |